LBA30_PR Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
Pharmacology, Toxicology and Pharmaceutical Science
1
2%
Other
2
3%
Unknown
34
56%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2022.
All research outputs
#4,120,019
of 27,789,359 outputs
Outputs from Annals of Oncology
#2,504
of 8,888 outputs
Outputs of similar age
#74,125
of 367,201 outputs
Outputs of similar age from Annals of Oncology
#86
of 332 outputs
Altmetric has tracked 27,789,359 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,888 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.9. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,201 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 332 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
